ADMA Biologics, Inc. (NASDAQ:ADMA) Shares purchased by Calamos Advisors LLC

Calamos Advisors LLC increased its position in ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report) up 122.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 250,185 shares of the biotech company, after acquiring an additional 137,749 shares during the quarter. Calamos Advisors LLC’s stake in ADMA Biologics was worth $1,131,000 at the end of the most recent reporting period.

Several other major investors have also recently bought and sold shares of ADMA. Arizona State Retirement System increased its stake in shares of ADMA Biologics by 4.9% in the fourth quarter. Arizona State Retirement System now owns 59,728 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 2,769 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in ADMA Biologics by 10.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 31,829 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 2,986 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in ADMA Biologics shares by 31.3% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 15,000 shares of the biotech company worth $54,000, after purchasing an additional 3,572 shares in the last quarter. The Swiss National Bank increased its position in ADMA Biologics shares by 1.0% in the third quarter. The Swiss National Bank now owns 439,800 shares of the biotechnology company worth $1,574,000 after purchasing an additional 4,300 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY increased its position in shares of ADMA Biologics by 61.5% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 11,565 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 4,403 shares during the last quarter. 75.68% of the shares are currently owned by hedge funds and other institutional investors.

ADMA Biologics Price Performance

ADMA shares opened at $6.27 on Monday. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.16 and a quick ratio of 1.69. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -48.23 and a beta of 0.46. The company’s 50-day moving average is $5.96 and its two-hundred-day moving average is $4.78. ADMA Biologics, Inc. has a 12-month low of $3.06 and a 12-month high of $6.76.

ADMA Biologics (NASDAQ:ADMA – Get Free Report) last reported its quarterly results on Wednesday, February 28. The biotechnology company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. The company had revenue of $73.90 million for the quarter, compared to analyst estimates of $73.50 million. Analysts predict that ADMA Biologics, Inc. will post a profit per share of 0.3 for the current year.

Wall Street analysts predict growth

A number of stock analysts have recently weighed in on the stock. Mizuho raised their price target on shares of ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, March 1. HC Wainwright reiterated a “buy” rating and issued a $7.50 price target (up from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26. Finally, Cantor Fitzgerald raised their price objective on ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average Buy rating and an average price target of $7.88.

Check out our latest stock report on ADMA Biologics

Insider buying and selling at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 49,887 shares of the company’s stock in a transaction dated Monday, March 18. The shares sold at an average price of $6.01, for a total value of $299,820.87. Following the transaction, the director now owns 2,527,500 shares of the company’s stock, valued at $15,190,275. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 639,895 shares of the company’s stock worth $3,927,169 in the last quarter. 6.00% of the shares are currently owned by company insiders.

Company profile ADMA Biologics

(Free report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in the development, manufacturing and marketing of specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immunoglobulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed Hepatitis B exposures.

read more

Would you like to see which other hedge funds own ADMA? Visit HoldingsChannel.com for the latest 13F filings and insider transactions for ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report).

Receive daily news and reviews for ADMA Biologics – Enter your email address below to receive a daily summary of the latest news and analyst ratings for ADMA Biologics and related companies with MarketBeat.com’s FREE daily email newsletter.